Diagnosis & Treatments

How is Urticaria/Angioedema diagnosed?

Diagnosis of Urticaria/Angioedema

Diagnosis of hives (urticaria) and angioedema is primarily based on clinical evaluation.

 

  • Physical examination: Assessment of skin lesions (welts) or swollen areas.
  • Medical history: Review of symptom onset, duration, potential triggers, and prior allergic reactions.
  • Laboratory tests: In selected cases, blood tests may be performed to evaluate for underlying conditions.
  • Allergy testing: Skin prick tests or other allergy evaluations may be used to identify possible allergens contributing to symptoms.
Diagnosis & Treatments

How is Urticaria/Angioedema treated?

Treatments for Urticaria/Angioedema

1. Acute Urticaria

 1-1. Course and management

Acute urticaria is generally self-limited and often improves with minimal intervention.

 1-2. Antihistamines

  • First-generation antihistamines (e.g., hydroxyzine, diphenhydramine) are effective but may cause sedation.
  • Second-generation antihistamines (e.g., loratadine, fexofenadine, cetirizine) are equally effective and preferred due to less sedation.

 1-3. Severe episodes

Intramuscular epinephrine (1:1,000, 0.01 mg/kg, maximum 0.5 mg) may be administered for acute, severe urticaria or angioedema, though it is rarely needed.

 1-4. Corticosteroids

A short course of oral corticosteroids may be considered for severe cases unresponsive to antihistamines.

 

2. Inducible Urticaria

 2-1. Primary management

Avoidance of the triggering stimulus is the most effective approach, though it can be challenging (e.g., in cholinergic urticaria).

 2-2. Antihistamines

Antihistamines, with dose escalation when necessary, should be tried in all cases, though response rates vary.

 

3. Chronic Urticaria

 3-1. Mainstay therapy

Non-sedating or low-sedating H1 antihistamines are the first-line treatment.

If symptoms persist, up-dosing up to four times the standard dose may be considered.

 3-2. Adjunctive agents

Addition of H2 antihistamines or leukotriene receptor antagonists (e.g., montelukast) may be considered, though evidence of benefit is limited.

 3-3. Corticosteroids

Short courses of oral corticosteroids may help in poorly controlled cases, but long-term use is not recommended.

 3-4. Biologic therapy

Omalizumab (anti-IgE monoclonal antibody) is FDA-approved for chronic urticaria in patients 12 years and older.

 3-5. Other immunomodulators

Off-label agents include cyclosporine, tacrolimus, mycophenolate, dapsone, hydroxychloroquine, sulfasalazine, and azathioprine.